MX355434B - Compuesto de pirazin-carboxamida. - Google Patents
Compuesto de pirazin-carboxamida.Info
- Publication number
- MX355434B MX355434B MX2014008647A MX2014008647A MX355434B MX 355434 B MX355434 B MX 355434B MX 2014008647 A MX2014008647 A MX 2014008647A MX 2014008647 A MX2014008647 A MX 2014008647A MX 355434 B MX355434 B MX 355434B
- Authority
- MX
- Mexico
- Prior art keywords
- egfr
- mutation
- positive
- carboxamide compound
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Problema Se proporciona un compuesto que resulta de utilidad como inhibidor de la actividad quinasa con mutación T790M en el EGFR. Medios de solución Los inventores de la presente han investigado un compuesto que tiene una acción inhibidora sobre una quinasa con mutación T790M en el EGFR, y han hallado que un compuesto de pirazin-carboxamida tiene una acción inhibidora en una quinasa con mutación T790M en el EGFR, con lo cual se ha completado la presente invención. El compuesto de pirazin-carboxamida de la presente invención tiene una acción inhibidora sobre una quinasa con mutación T790M en el EGFR, y se puede usar como agente para prevenir y/o tratar el cáncer positivo con mutación T790M en el EGFR; en otra modalidad, cáncer de pulmón positivo con mutación T790M en el EGRF; aún en otra modalidad, cáncer de pulmón de células no pequeñas positivo con mutación T790M en el EGFR; también en otra modalidad, cáncer de proteínas positivo con mutación T790M en el EGRF; en una modalidad diferente, cáncer de pulmón de proteínas positivo con mutación T790M en el EGRF; aún en una modalidad diferente, cáncer resistente al inhibidor de la tirosina quinasa en el EGFR; aún en una modalidad diferente, cáncer de pulmón resistente al inhibidor de la tirosina quinasa en el EGFR; y también en otra modalidad diferente, cáncer de pulmón de células no pequeñas resistente al inhibidor de la tirosina quinasa en el EGFR y similares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012007525 | 2012-01-17 | ||
PCT/JP2013/050579 WO2013108754A1 (ja) | 2012-01-17 | 2013-01-15 | ピラジンカルボキサミド化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014008647A MX2014008647A (es) | 2014-11-25 |
MX355434B true MX355434B (es) | 2018-04-18 |
Family
ID=48799179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008647A MX355434B (es) | 2012-01-17 | 2013-01-15 | Compuesto de pirazin-carboxamida. |
Country Status (30)
Country | Link |
---|---|
US (1) | US9085540B2 (es) |
EP (1) | EP2805940B1 (es) |
JP (1) | JP5532366B2 (es) |
KR (1) | KR101985050B1 (es) |
CN (1) | CN104080774B (es) |
AR (1) | AR089727A1 (es) |
AU (1) | AU2013210438B2 (es) |
BR (1) | BR112014017466A8 (es) |
CA (1) | CA2860765C (es) |
CY (1) | CY1118644T1 (es) |
DK (1) | DK2805940T3 (es) |
EA (1) | EA026353B1 (es) |
ES (1) | ES2613399T3 (es) |
HK (1) | HK1203491A1 (es) |
HR (1) | HRP20170226T1 (es) |
HU (1) | HUE033177T2 (es) |
IL (1) | IL233437A (es) |
LT (1) | LT2805940T (es) |
ME (1) | ME02648B (es) |
MX (1) | MX355434B (es) |
PH (1) | PH12014501456A1 (es) |
PL (1) | PL2805940T3 (es) |
PT (1) | PT2805940T (es) |
RS (1) | RS55704B1 (es) |
SI (1) | SI2805940T1 (es) |
SM (1) | SMT201700094B (es) |
TW (1) | TWI532727B (es) |
UA (1) | UA111010C2 (es) |
WO (1) | WO2013108754A1 (es) |
ZA (1) | ZA201405045B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9598398B2 (en) | 2013-04-04 | 2017-03-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015061247A2 (en) | 2013-10-21 | 2015-04-30 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
MX2016007111A (es) * | 2013-12-05 | 2016-08-11 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton. |
MX2016007171A (es) * | 2013-12-05 | 2016-09-08 | Hoffmann La Roche | Compuestos de heteroaril piridona y azapiridona con funcionalidad electrofila. |
TW201622744A (zh) | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | 癌症之組合療法 |
EA201692479A1 (ru) * | 2014-05-28 | 2017-03-31 | Астеллас Фарма Инк. | Фармацевтическая композиция, которая содержит соединение пиразинкарбоксамида в качестве активного ингредиента |
CN105085489B (zh) | 2014-11-05 | 2019-03-01 | 益方生物科技(上海)有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
CN107207468A (zh) * | 2015-01-28 | 2017-09-26 | 安斯泰来制药株式会社 | 吡嗪甲酰胺化合物的制造方法及其合成中间体 |
JP6112530B2 (ja) * | 2015-04-27 | 2017-04-12 | アステラス製薬株式会社 | 安定化されてなる医薬組成物 |
JP2018104290A (ja) * | 2015-04-28 | 2018-07-05 | アステラス製薬株式会社 | ピラジンカルボキサミド化合物を有効成分とする医薬組成物 |
CA2987054A1 (en) * | 2015-06-02 | 2016-12-08 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
EP3310771B1 (en) * | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
JP2019014653A (ja) * | 2015-11-27 | 2019-01-31 | アステラス製薬株式会社 | がん免疫を介したがん治療方法 |
EP3401309A4 (en) * | 2015-12-24 | 2019-11-27 | Kyowa Kirin Co., Ltd. | UNSATURATED AMIDE COMPOUND ALPHA, BETA |
WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
TW201827052A (zh) * | 2016-10-26 | 2018-08-01 | 日商安斯泰來製藥股份有限公司 | 安定的醫藥組成物 |
CN108419436B (zh) * | 2016-12-09 | 2021-05-04 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途 |
SG11201912770SA (en) * | 2017-06-23 | 2020-01-30 | Kyowa Kirin Co Ltd | a, ß-UNSATURATED AMIDE COMPOUND |
TWI798334B (zh) * | 2018-01-31 | 2023-04-11 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Erbb/btk抑制劑 |
JP7201800B2 (ja) * | 2018-09-30 | 2023-01-10 | メッドシャイン ディスカバリー インコーポレイテッド | Flt3およびaxlの阻害剤としての3,9-ジアザスピロ[5,5]ウンデカン系化合物 |
CN112062728A (zh) * | 2019-05-25 | 2020-12-11 | 上海鑫凯化学科技有限公司 | 一种3,5-二氯-6-乙基吡嗪甲酰胺的合成方法 |
CN114728905A (zh) * | 2019-11-13 | 2022-07-08 | 基因泰克公司 | 治疗性化合物及使用方法 |
CN111266090B (zh) * | 2020-02-19 | 2022-11-15 | 渤海大学 | 一种快速吸附和选择性分离阳离子染料污染物的吸附分离材料及其应用 |
EP4159731A1 (en) * | 2020-06-01 | 2023-04-05 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | New pyrazine compound |
CN113943288A (zh) * | 2020-07-17 | 2022-01-18 | 微境生物医药科技(上海)有限公司 | 5,6-二氢吡嗪并[2,3-c]异喹啉化合物 |
WO2022195355A1 (en) | 2021-03-15 | 2022-09-22 | Novartis Ag | Benzisoxazole derivatives and uses thereof |
US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
CA2537978C (en) | 2003-09-15 | 2011-08-02 | Wyeth | Substituted quinolines as protein tyrosine kinase enzyme inhibitors |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
UA85706C2 (en) | 2004-05-06 | 2009-02-25 | Уорнер-Ламберт Компани Ллси | 4-phenylaminoquinazolin-6-yl amides |
WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
CA2920996A1 (en) | 2007-10-19 | 2009-04-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
VN29259A1 (en) * | 2008-04-16 | 2012-04-25 | Portola Pharm Inc | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
CA2723205C (en) * | 2008-04-16 | 2017-03-14 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors |
KR101892989B1 (ko) | 2008-06-27 | 2018-08-30 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
WO2010129053A2 (en) * | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
MX2011011875A (es) * | 2009-05-08 | 2011-12-08 | Astellas Pharma Inc | Compuesto de carboxamida heterociclica diamino. |
US20130137709A1 (en) | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
-
2013
- 2013-01-15 US US13/990,006 patent/US9085540B2/en active Active
- 2013-01-15 DK DK13738947.4T patent/DK2805940T3/en active
- 2013-01-15 AR ARP130100118A patent/AR089727A1/es unknown
- 2013-01-15 JP JP2013513321A patent/JP5532366B2/ja not_active Expired - Fee Related
- 2013-01-15 ME MEP-2017-43A patent/ME02648B/me unknown
- 2013-01-15 PT PT137389474T patent/PT2805940T/pt unknown
- 2013-01-15 SI SI201330544A patent/SI2805940T1/sl unknown
- 2013-01-15 KR KR1020147021135A patent/KR101985050B1/ko active IP Right Grant
- 2013-01-15 WO PCT/JP2013/050579 patent/WO2013108754A1/ja active Application Filing
- 2013-01-15 AU AU2013210438A patent/AU2013210438B2/en not_active Ceased
- 2013-01-15 RS RS20170190A patent/RS55704B1/sr unknown
- 2013-01-15 MX MX2014008647A patent/MX355434B/es active IP Right Grant
- 2013-01-15 PL PL13738947T patent/PL2805940T3/pl unknown
- 2013-01-15 CN CN201380005885.8A patent/CN104080774B/zh active Active
- 2013-01-15 UA UAA201409176A patent/UA111010C2/uk unknown
- 2013-01-15 CA CA2860765A patent/CA2860765C/en not_active Expired - Fee Related
- 2013-01-15 TW TW102101457A patent/TWI532727B/zh not_active IP Right Cessation
- 2013-01-15 BR BR112014017466A patent/BR112014017466A8/pt not_active Application Discontinuation
- 2013-01-15 HU HUE13738947A patent/HUE033177T2/en unknown
- 2013-01-15 EP EP13738947.4A patent/EP2805940B1/en active Active
- 2013-01-15 EA EA201491371A patent/EA026353B1/ru not_active IP Right Cessation
- 2013-01-15 ES ES13738947.4T patent/ES2613399T3/es active Active
- 2013-01-15 LT LTEP13738947.4T patent/LT2805940T/lt unknown
-
2014
- 2014-06-24 PH PH12014501456A patent/PH12014501456A1/en unknown
- 2014-06-29 IL IL233437A patent/IL233437A/en not_active IP Right Cessation
- 2014-07-10 ZA ZA2014/05045A patent/ZA201405045B/en unknown
-
2015
- 2015-04-22 HK HK15103891.7A patent/HK1203491A1/xx not_active IP Right Cessation
-
2017
- 2017-02-10 SM SM201700094T patent/SMT201700094B/it unknown
- 2017-02-10 HR HRP20170226TT patent/HRP20170226T1/hr unknown
- 2017-02-20 CY CY20171100230T patent/CY1118644T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX355434B (es) | Compuesto de pirazin-carboxamida. | |
PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
PH12017502141A1 (en) | Compounds and their methods of use | |
MY170904A (en) | Ret inhibitor | |
PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
PH12014502573A1 (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
NZ710111A (en) | Quinoline and quinoxaline amides as modulators of sodium channels | |
MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
MD20150071A2 (ro) | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni | |
MX2013010016A (es) | Compuestos de quinazolina sustituidos con alquino y metodos uso. | |
MX351863B (es) | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. | |
NZ736970A (en) | Process methods for phosphatidylinositol 3-kinase inhibitors | |
PH12015501038A1 (en) | Inhibitors of iap | |
GEP20186871B (en) | Benzamide and nicotinamide compounds and methods of using same | |
PH12016500735A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
PH12014501979B1 (en) | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |